Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?
Cancer therapies
Latent infections
Migrant
Screening
Universal screening
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
01
12
2020
accepted:
26
02
2021
pubmed:
26
3
2021
medline:
16
10
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
Contention surrounds how best to screen patients for latent and undiagnosed infection prior to cancer treatment. Early treatment and prophylaxis against reactivation may improve infection-associated morbidity. This study sought to examine rates of screening and prevalence of latent infection in overseas-born patients receiving cancer therapies. A single-centre retrospective audit of 952 overseas-born patients receiving chemotherapy, targeted agents and immunotherapy between January 1 and December 31 2019 was undertaken at Peter MacCallum Cancer Centre. Pre-treatment screening for hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV), latent tuberculosis (LTBI), toxoplasmosis and strongyloidiasis was audited. Approximately half of our overseas-born patients were screened for HBV (58.9%) and HCV (50.7%). Fewer patients were screened for HIV (30.5%), LTBI (18.3%), strongyloidiasis (8.6%) or toxoplasmosis (8.1%). Although 59.7% of our patients were born in countries with high epidemiological risk for latent infection, according to World Health Organization data, 35% were not screened for any infection prior to commencement of therapy. The prevalence of latent infections amongst overseas-born patients with cancer, and complexities associated with risk-based screening, likely supports universal latent infection screening amongst this higher-risk cohort.
Identifiants
pubmed: 33763725
doi: 10.1007/s00520-021-06116-w
pii: 10.1007/s00520-021-06116-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6193-6200Informations de copyright
© 2021. Crown.
Références
Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. (2016) Prevention and treatment of cancer-related infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. 14(7):882
Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5(4):497–505
pubmed: 30653226
pmcid: 6459217
doi: 10.1001/jamaoncol.2018.6437
Kurizky PS, dos Santos Neto LL, Aires RB, da Mota LMH, Gomes CM (2020) Opportunistic tropical infections in immunosuppressed patients. Best Pract Res Clin Rheumatol 101509
2019 HBMDCTCSG. Hepatitis B management during immunosuppression for haematological and solid-organ malignancies: an Australian consensus statement 2019 Melbourne2019
Menzies S, Curry L, Turnbull C (2015) Active TB in cancer patients: a missed screening opportunity? Eur Respir J 46(suppl 59):PA2985
Shu C-C, Liao K-M, Chen Y-C, Wang J-J, Ho C-H (2019) The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep 9(1):11901
pubmed: 31417132
pmcid: 6695428
doi: 10.1038/s41598-019-48395-8
Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanović V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, de Wit S, Gatell JM, Gazzard B, d’Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD, on behalf of the HIDES Study Group (2019) Improving the evidence for indicator condition guided HIV testing in Europe: results from the HIDES II Study – 2012 – 2015. PLoS One 14(8):e0220108
pubmed: 31408476
pmcid: 6692030
doi: 10.1371/journal.pone.0220108
Molto J, Moran T, Sirera G, Clotet B (2015) Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Transl Lung Cancer Res 4(6):678–688
pubmed: 26798577
pmcid: 4700212
MacLachlan JH, Romero N, Higgins N, Coutts R, Chan R, Stephens N et al (2020) Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance. Aust N Z J Public Health 44(1):59–64
pubmed: 31535439
doi: 10.1111/1753-6405.12934
Yang C, Qin B, Yuan Z, Chen L (2016) Zhou H-y. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol 15(4):501–511
pubmed: 27236149
Smieja MJ, Marchetti CA, Cook DJ, Smaill FM (2000) Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2:CD001363
Group ISS (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373(9):795–807
doi: 10.1056/NEJMoa1506816
Alshuwaykh O, Kwo PY (2020) HCV treatment in 2020: how to translate highly effective therapies into elimination strategies. Hepatology. 2:72–74
Torres HA, Pundhir P, Mallet V (2019) Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. 157(4):909–916
pubmed: 30797794
doi: 10.1053/j.gastro.2019.01.271
Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih Y-CT, Chavez-MacGregor M et al (2019) Cost-effectiveness analysis of hepatitis b virus screening and management in patients with hematologic or solid malignancies anticipating immunosuppressive cancer therapy. JCO Clin Cancer Inform 3:1–12
pubmed: 30892921
doi: 10.1200/CCI.18.00097
Hwang J, Granwehr B, Torres H (2015) HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract 11:384–390
pubmed: 26243649
pmcid: 4575402
doi: 10.1200/JOP.2015.005116
Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V (2017) The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin 67(5):411–431
pubmed: 28683174
pmcid: 5591069
doi: 10.3322/caac.21403
Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS (2015) Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol 33(19):2212–2220
pubmed: 25964247
pmcid: 4477791
doi: 10.1200/JCO.2015.61.3745
ASHM. HBV Testing Policy. In: Committee ER, editor. 2020
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10(1):1–98
pubmed: 26563120
doi: 10.1007/s12072-015-9675-4
Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A et al (2016) Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 16(5):606–617
pubmed: 27599653
doi: 10.1016/S1473-3099(16)00118-3
Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, et al. (2020) Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. JCO2001757
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67(4):1560–1599
pubmed: 29405329
doi: 10.1002/hep.29800
Diseases AAftSoL (2014) AASLDIDSA Recommendations for testing, managing, and treating hepatitis C
Liver EAFTSOT (2017) EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370–398
doi: 10.1016/j.jhep.2017.03.021
Liver EAfTSoT (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461–511
doi: 10.1016/j.jhep.2018.03.026
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB et al (2006) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55(RR-14):1–17 quiz CE1-4
pubmed: 16988643
Salvant Valentine S, Caldwell J, Tailor A (2020) Effect of CDC 2006 Revised HIV testing recommendations for adults, Adolescents, pregnant women, and newborns on state laws, 2018. Public Health Rep 135(1_suppl):189S–196S
pubmed: 32735201
pmcid: 7407059
doi: 10.1177/0033354920930146
Turnbull L, Bell C, Child F (2017) Tuberculosis (NICE clinical guideline 33). Arch Dis Child Educ Pract Ed 102(3):136–142
pubmed: 27974357
doi: 10.1136/archdischild-2016-310870
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E et al (2017) Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis 64(2):e1–e33
pubmed: 27932390
doi: 10.1093/cid/ciw694
Sullivan R, Gaskell C, Lewis CR, Vollmer-Conna U, Post JJ (2019) Infectious disease screening in patients prior to undergoing immunosuppressive therapy. Int J Clin Pract 73(10):e13406
pubmed: 31441189
doi: 10.1111/ijcp.13406
Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK (2018) Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis 18(1):42
pubmed: 29338702
pmcid: 5771208
doi: 10.1186/s12879-017-2908-5
Global H. AIDS statistics: 2019 Factsheet. UNAIDS. 2019.
Te HS, Jensen DM (2010) Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14(1):1–21
pubmed: 20123436
doi: 10.1016/j.cld.2009.11.009
Bennett JE, Dolin R, Blaser MJ (2020) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Ninth ed. Elsevier, Philadelphia
Angelidakis G, Hwang JP, Dandachi D, Economides MP, Hosry J, Granwehr BP, Torres HA (2018) Universal screening for hepatitis C: a needed approach in patients with haematologic malignancies. J Viral Hepat 25(9):1102–1104
pubmed: 29660201
doi: 10.1111/jvh.12913
Sun W-C, Hsu P-I, Yu H-C, Lin K-H, Tsay F-W, Wang H-M, Tsai TJ, Chen WC, Lai KH, Cheng JS (2015) The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLoS One 10(2):e0116978
pubmed: 25658926
pmcid: 4319781
doi: 10.1371/journal.pone.0116978
Day FL, Karnon J, Rischin D (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29(24):3270–3277
pubmed: 21788556
doi: 10.1200/JCO.2011.35.1635
Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP, Mitsuyasu R, Pantanowitz L (2010) Time for oncologists to opt in for routine opt-out HIV testing? JAMA. 304(3):334–339
pubmed: 20639567
pmcid: 3160789
doi: 10.1001/jama.2010.752
Merz L, Zimmermann S, Peters S, Cavassini M, Darling KE (2016) Investigating barriers in HIV-testing oncology patients: the IBITOP study, Phase I. Oncologist. 21(10):1176–1182
pubmed: 27440062
pmcid: 5061530
doi: 10.1634/theoncologist.2016-0107
Lin YD, Eades L, Nair A, Korman TM, Woolley I (2020) Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing? Intern Med J 50(3):293–298
pubmed: 31566841
doi: 10.1111/imj.14641
Dobler CC, Cheung K, Nguyen J, Martin A (2017) Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J 50(2):1700157
pubmed: 28838977
doi: 10.1183/13993003.00157-2017
Hasan T, Au E, Chen S, Tong A, Wong G (2018) Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 8(9):e022445
pubmed: 30209157
pmcid: 6144320
doi: 10.1136/bmjopen-2018-022445
Dale KD, Trauer JM, Dodd PJ, Houben R, Denholm JT (2018) Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia. Eur Respir J. 52(6)
Feletto E, Sitas F (2015) Quantifying disparities in cancer incidence and mortality of Australian residents of New South Wales (NSW) by place of birth: an ecological study. BMC Public Health 15:823
pubmed: 26306859
pmcid: 4548689
doi: 10.1186/s12889-015-2141-3
Haddad FG, Kattan C, Kattan J (2020) Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis? Immunotherapy. 12(11):759–762
pubmed: 32517560
doi: 10.2217/imt-2020-0069
Sanchez-Montalva A, Salvador F, Ruiz-Camps I, Barba P, Valcarcel D, Sulleiro E et al (2016) Imported disease screening prior to chemotherapy and bone marrow transplantation for oncohematological malignancies. Am J Trop Med Hyg 95(6):1463–1468
pubmed: 27928093
pmcid: 5154468
doi: 10.4269/ajtmh.16-0458
Martin J, Mak D (2006) Changing faces: a review of infectious disease screening of refugees by the Migrant Health Unit, Western Australia in 2003 and 2004. Med J Aust 185:607–610
pubmed: 17181502
doi: 10.5694/j.1326-5377.2006.tb00726.x
Speare R, Durrheim DN (2004) Strongyloides serology--useful for diagnosis and management of strongyloidiasis in rural Indigenous populations, but important gaps in knowledge remain. Rural Remote Health 4(4):264
pubmed: 15887986
Hornum M, Mortensen KL, Kamper AL, Andersen AB (2008) Limitations of the QuantiFERON-TB Gold test in detecting Mycobacterium tuberculosis infection in immunocompromised patients. Eur J Intern Med 19(2):137–139
pubmed: 18249311
doi: 10.1016/j.ejim.2007.03.020